Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion type Assertion NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_head.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion evidence source_evidence_literature NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion SIO_000772 22781593 NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion wasDerivedFrom befree-20150227 NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion wasGeneratedBy ECO_0000203 NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.